~~<i id='24E70FA2C2'><strike id='24E70FA2C2'><tt id='24E70FA2C2'><pre id='24E70FA2C2'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

entertainment

author：focus 2025-09-27 13:04:01 - browse：6336

glum Benjamin — health insurance coverage from STAT — Adobe

Startup insurers Oscar Health, Bright Health, and Clover Health have hemorrhaged money since going public within the past two years. All three used their stage time at the J.P. Morgan Healthcare Conference to make the case that their drastic decisions — like fully exiting some insurance markets — will deliver the profitability investors are demanding.

“Insurance company profitability is the number one goal,” Oscar CEO Mario Schlosser said in an interview with STAT in San Francisco.

“We are actually absolutely focused on profitability right now,” Clover CEO Andrew Toy said during his presentation on Wednesday.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： SAMSHA loosens regulations on methadone treatment centers

explore

knowledge

explore

leisure time

focus

knowledge

AnnaMoneymaker/GettyImagesWASHINGTON—TheSupremeCourtwillthisMarchhearargumentscenteredonthegovernmen

WSS

Time to name cancers by genetics, not organ of origin, expert says

With Wegovy coverage, Medicare patients may face high costs

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Novo Nordisk to expand supply of Wegovy for U.S. patients

What Kate Middleton's cancer revelation might teach the world

focus

entertainment

explore

United colonoscopy coverage change 'may cost lives,' doctors say

What we need to know about Arena Bioworks

Heart attack and stroke risk calculators need revising

Readout Newsletter: Illumina, CRISPR, Regeneron

After affirmative action ruling, medical educators look to 'holistic review'

What Kate Middleton's cancer revelation might teach the world

23andMe had bad news about my health. I wish a person had delivered it

The lessons of Aduhelm, an Alzheimer's drug that was not to be

The high cost of giving birth even with insurance

Diabetes management: Digital health tools fall short, study says

knowledge

Woodcock on FDA’s accelerated approval and her next chapter

Vertigo drug brings hope for rare neuron disorder, Niemann

CRISPR technology availability, affordability needs to be expanded

New Ultima Genomics DNA sequencer can read genome for $100

ARCH Venture Partners is raising $3 billion for a life sciences fund

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

explore

leisure time

focus

knowledge